Mark Brantly

机构：University of Florida, University of Florida Health Science Center · ORCID：0000-0003-0189-1565

发表论文 276 篇 · 总被引 13518 次 · h-index 64

代表论文

• Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA) (2024 · Gastroenterology · 被引 29)
• Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease–antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study (2024 · ERJ Open Research · 被引 11)
• Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease (2024 · Alimentary Pharmacology & Therapeutics · 被引 11)
• Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study (2024 · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 被引 10)
• Monocyte NLRP3 inflammasome and interleukin-1β activation modulated by alpha-1 antitrypsin therapy in deficient individuals (2024 · Thorax · 被引 6)
• Alpha-defensins inhibit ERK/STAT3 signaling during monocyte-macrophage differentiation and impede macrophage function (2023 · Respiratory Research · 被引 6)